IntelliPharmaCeutics International Inc. (IPCI) EPS Estimated At $-0.05

March 14, 2018 - By reb123z

 IntelliPharmaCeutics International Inc. (IPCI) EPS Estimated At $ 0.05

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock decreased 9.27% or $0.0573 during the last trading session, reaching $0.5606. About 562,884 shares traded or 56.33% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 14, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, February 12. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has “Hold” rating given on Friday, February 16 by Maxim Group. The firm has “Buy” rating by Maxim Group given on Thursday, December 31. Maxim Group maintained the shares of IPCI in report on Friday, June 30 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Tuesday, June 6. Maxim Group maintained it with “Buy” rating and $600 target in Friday, July 21 report. As per Monday, March 5, the company rating was maintained by H.C. Wainwright.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $19.44 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: which released: “Intellipharmaceutics Announces US$4 Million Registered Direct Offering” on October 11, 2017, also with their article: “Intellipharmaceutics International Inc.” published on July 27, 2017, published: “Intellipharmaceutics Provides Operational Update” on January 24, 2018. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: and their article: “FDA declines to approve Intellipharma’s opioid painkiller” published on September 25, 2017 as well as‘s news article titled: “Intellipharmaceutics Announces Closing of US$4 Million Financing” with publication date: October 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.